Michael Okunewitch
Stock Analyst at Maxim Group
(0)
# 4665
Out of 5,218 analysts
21
Total ratings
17.65%
Success rate
-18.14%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Citius Oncology | Initiates Coverage On: Buy | 3 | 1.08 | 177.78% | 1 | Nov 27, 2024 | |
Ocugen | Initiates Coverage On: Buy | 4 | 0.87 | 359.77% | 1 | Oct 15, 2024 | |
FibroBiologics | Initiates Coverage On: Buy | 12 | 2.19 | 447.95% | 1 | Sep 24, 2024 | |
Longeveron | Maintains: Buy | 15 6 | 1.84 | 226.09% | 2 | Aug 27, 2024 | |
Chemomab Therapeutic... | Initiates Coverage On: Buy | 4 | 1.59 | 151.57% | 1 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 3 12 | 2.24 | 435.71% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 2 | n/a | n/a | 1 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 24 | 7.08 | 238.98% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 1.45 | 313.79% | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 108 18 | 3.3 | 445.45% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 225 | 1.19 | 18807.56% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 25 | 17.14 | 45.86% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 1.46 | 310.96% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 4 | 0.37 | 981.08% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 120 | n/a | n/a | 1 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 25 | 1.35 | 1751.85% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 100 | 2.78 | 3497.12% | 1 | Nov 30, 2021 |